Egetis has rapidly transferred all but one German patient, supporting the launch and indicating positive acceptance of Emcitate at a favorable list price, supporting future European sales. The upcoming pre-NDA meeting with the FDA is significant in our view, setting the scene and the timetable ahead of the US launch.
LÄS MER
